{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T18:38:39Z","timestamp":1787855919004,"version":"build-2784847793"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81800344"],"award-info":[{"award-number":["81800344"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82000385"],"award-info":[{"award-number":["82000385"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81970340"],"award-info":[{"award-number":["81970340"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2020A1515011095"],"award-info":[{"award-number":["2020A1515011095"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Obesity is a well-defined risk factor for heart failure with preserved ejection fraction (HFpEF), but it is associated with a better prognosis in patients with diagnosed HFpEF. The paradoxically poor prognosis in nonobese patients with HFpEF may be driven by a subset of high-risk patients, which suggests that the nonobese HFpEF subpopulation is heterogeneous.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Latent class analysis (LCA) was adopted to identify the potential subgroups of 623 nonobese patients enrolled in the TOPCAT trial. The baseline characteristics of the identified nonobese subgroups were compared with each other and with the obese patients. The risks of all-cause, cardiovascular, and noncardiovascular mortality, and an HF composite outcome were also compared.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Two subgroups of nonobese patients with HFpEF (the physiological non-obesity and the pathological non-obesity) were identified. The obese patients were younger than both nonobese subgroups. The clinical profile of patients with pathological non-obesity was poorer than that of patients with physiological non-obesity. They had more comorbidities, more severe HF, poorer quality of life, and lower levels of physical activity. Patients with pathological non-obesity showed low serum hemoglobin and albumin levels. After 2 years of follow-up, more patients in the pathological group lost \u2265 10% of body weight compared with those in the physiological group (11.34% vs. 4.19%, <jats:italic>P<\/jats:italic> = 0.009). The prognostic implications of the two subgroups were opposite. Compared to patients with obesity, patients with physiological non-obesity had a 47% decrease in the risk of HF composite outcome (hazard ratio [HR] 0.53, 95% confidence interval [CI] 0.40\u20130.70, <jats:italic>P<\/jats:italic>&lt;0.001) and a trend of decreased all-cause mortality risk (HR 0.75, 95% CI 0.55\u20131.01, <jats:italic>P<\/jats:italic>=0.06), while patients with pathological non-obesity had a 59% increase (HR 1.59, 95% CI 1.24\u20132.02, <jats:italic>P<\/jats:italic>&lt;0.001) in all-cause mortality risk.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Two subgroups of nonobese patients with HFpEF with distinct clinical profiles and prognostic implications were identified. The low BMI was likely physiological in one group but pathological in the other group. Using a data-driven approach, our study provided an alternative explanation for the \u201cobesity paradox\u201d that the poor prognosis of nonobese patients with HFpEF was driven by a pathological subgroup.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-022-02626-4","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T19:03:06Z","timestamp":1667415786000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Distinct implications of body mass index in different subgroups of nonobese patients with heart failure with preserved ejection fraction: a latent class analysis of data from the TOPCAT trial"],"prefix":"10.1186","volume":"20","author":[{"given":"Bin","family":"Dong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiling","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruicong","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weihao","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiangui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfei","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yugang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9818-0454","authenticated-orcid":false,"given":"Chen","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,2]]},"reference":[{"issue":"10","key":"2626_CR1","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nrcardio.2017.65","volume":"14","author":"SM Dunlay","year":"2017","unstructured":"Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2017;14(10):591\u2013602.","journal-title":"Nat Rev Cardiol"},{"issue":"2","key":"2626_CR2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.pcad.2018.05.005","volume":"61","author":"TB Horwich","year":"2018","unstructured":"Horwich TB, Fonarow GC, Clark AL. Obesity and the obesity paradox in heart failure. Prog Cardiovasc Dis. 2018;61(2):151\u20136.","journal-title":"Prog Cardiovasc Dis."},{"issue":"6","key":"2626_CR3","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1161\/CIRCULATIONAHA.106.679779","volume":"116","author":"S Kenchaiah","year":"2007","unstructured":"Kenchaiah S, Pocock SJ, Wang D, et al. Body mass index and prognosis in patients with chronic heart failure - Insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Circulation. 2007;116(6):627\u201336.","journal-title":"Circulation"},{"issue":"10","key":"2626_CR4","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1016\/j.amjcard.2015.02.024","volume":"115","author":"A Sharma","year":"2015","unstructured":"Sharma A, Lavie CJ, Borer JS, et al. Meta-analysis of the relation of body mass index to all-cause and cardiovascular mortality and hospitalization in patients with chronic heart failure. Am J Cardiol. 2015;115(10):1428\u201334.","journal-title":"Am J Cardiol"},{"issue":"13","key":"2626_CR5","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1161\/CIRCULATIONAHA.117.029617","volume":"137","author":"IJ Neeland","year":"2018","unstructured":"Neeland IJ, Poirier P, Despres JP. Cardiovascular and metabolic heterogeneity of obesity: clinical challenges and implications for management. Circulation. 2018;137(13):1391\u2013406.","journal-title":"Circulation"},{"issue":"2","key":"2626_CR6","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1016\/j.mayocp.2016.11.001","volume":"92","author":"S Carbone","year":"2017","unstructured":"Carbone S, Lavie CJ, Arena R. Obesity and heart failure: focus on the obesity paradox. Mayo Clin Proc. 2017;92(2):266\u201379.","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"2626_CR7","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.jchf.2018.09.006","volume":"6","author":"A Pandey","year":"2018","unstructured":"Pandey A, Patel KV, Vaduganathan M, et al. Physical activity, fitness, and obesity in heart failure with preserved ejection fraction. JACC Heart Fail. 2018;6(12):975\u201382.","journal-title":"JACC Heart Fail"},{"issue":"1","key":"2626_CR8","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1161\/CIRCULATIONAHA.116.026807","volume":"136","author":"M Obokata","year":"2017","unstructured":"Obokata M, Reddy Y, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation. 2017;136(1):6\u201319.","journal-title":"Circulation"},{"issue":"2","key":"2626_CR9","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jacc.2016.05.019","volume":"68","author":"DW Kitzman","year":"2016","unstructured":"Kitzman DW, Shah SJ. The HFpEF obesity phenotype: the elephant in the room. J Am Coll Cardiol. 2016;68(2):200\u20133.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2626_CR10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ahj.2009.10.026","volume":"159","author":"JR Kapoor","year":"2010","unstructured":"Kapoor JR, Heidenreich PA. Obesity and survival in patients with heart failure and preserved systolic function: a U-shaped relationship. Am Heart J. 2010;159(1):75\u201380.","journal-title":"Am Heart J"},{"issue":"9","key":"2626_CR11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002916","volume":"16","author":"C Chandramouli","year":"2019","unstructured":"Chandramouli C, Tay WT, Bamadhaj NS, et al. Association of obesity with heart failure outcomes in 11 Asian regions: A cohort study. PLos Med. 2019;16(9):e1002916.","journal-title":"PLos Med"},{"issue":"1","key":"2626_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jphys.2016.05.018","volume":"63","author":"A Kongsted","year":"2017","unstructured":"Kongsted A, Nielsen AM. Latent class analysis in health research. J Physiother. 2017;63(1):55\u20138.","journal-title":"J Physiother"},{"issue":"9","key":"2626_CR13","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.jid.2020.05.079","volume":"140","author":"L Naldi","year":"2020","unstructured":"Naldi L, Cazzaniga S. Research techniques made simple: latent class analysis. J Invest Dermatol. 2020;140(9):1676\u201380.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"2626_CR14","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.jchf.2019.09.009","volume":"8","author":"JB Cohen","year":"2020","unstructured":"Cohen JB, Schrauben SJ, Zhao L, et al. Clinical phenogroups in heart failure with preserved ejection fraction: detailed phenotypes, prognosis, and response to spironolactone. JACC Heart Fail. 2020;8(3):172\u201384.","journal-title":"JACC Heart Fail"},{"issue":"6","key":"2626_CR15","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1002\/ejhf.2169","volume":"23","author":"A Uijl","year":"2021","unstructured":"Uijl A, Savarese G, Vaartjes I, et al. Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction. Eur J Heart Fail. 2021;23(6):973\u201382.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"2626_CR16","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1016\/j.ahj.2011.09.007","volume":"162","author":"AS Desai","year":"2011","unstructured":"Desai AS, Lewis EF, Li R, et al. Rationale and design of the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction. Am Heart J. 2011;162(6):966\u201372.","journal-title":"Am Heart J"},{"issue":"1","key":"2626_CR17","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","volume":"131","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer MA, Claggett B, Assmann SF, et al. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131(1):34\u201342.","journal-title":"Circulation"},{"issue":"4","key":"2626_CR18","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1214\/17-AOAS1061","volume":"11","author":"M Fop","year":"2017","unstructured":"Fop M, Smart KM, Murphy TB. Variable selection for latent class analysis with application to low back pain diagnosis. Ann Appl Stat. 2017;11(4):2080\u2013110.","journal-title":"Ann Appl Stat"},{"issue":"7","key":"2626_CR19","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1253\/circj.CJ-11-1355","volume":"76","author":"S Hamaguchi","year":"2012","unstructured":"Hamaguchi S, Kinugawa S, Sobirin MA, et al. Mode of death in patients with heart failure and reduced vs. preserved ejection fraction: report from the registry of hospitalized heart failure patients. Circ J. 2012;76(7):1662\u20139.","journal-title":"Circ J"},{"issue":"5","key":"2626_CR20","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.jacc.2016.10.078","volume":"69","author":"M Vaduganathan","year":"2017","unstructured":"Vaduganathan M, Patel RB, Michel A, et al. Mode of death in heart failure with preserved ejection fraction. J Am Coll Cardiol. 2017;69(5):556\u201369.","journal-title":"J Am Coll Cardiol"},{"key":"2626_CR21","doi-asserted-by":"publisher","first-page":"l5657","DOI":"10.1136\/bmj.l5657","volume":"367","author":"RJ Desai","year":"2019","unstructured":"Desai RJ, Franklin JM. Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners. BMJ. 2019;367:l5657.","journal-title":"BMJ"},{"issue":"12","key":"2626_CR22","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1161\/CIRCULATIONAHA.119.040144","volume":"140","author":"BA Bergmark","year":"2019","unstructured":"Bergmark BA, Bhatt DL, McGuire DK, et al. Metformin use and clinical outcomes among patients with diabetes mellitus with or without heart failure or kidney dysfunction: observations from the SAVOR-TIMI 53 Trial. Circulation. 2019;140(12):1004\u201314.","journal-title":"Circulation"},{"key":"2626_CR23","doi-asserted-by":"publisher","first-page":"2567","DOI":"10.1002\/ehf2.13969","volume":"9","author":"M Choy","year":"2022","unstructured":"Choy M, Liang W, He J, et al. Phenotypes of heart failure with preserved ejection fraction and effect of spironolactone treatment. ESC Heart Fail. 2022;9:2567\u201375.","journal-title":"ESC Heart Fail"},{"issue":"7","key":"2626_CR24","doi-asserted-by":"publisher","first-page":"1561","DOI":"10.1038\/s41366-020-0563-1","volume":"44","author":"TM Mandviwala","year":"2020","unstructured":"Mandviwala TM, Basra SS, Khalid U, et al. Obesity and the paradox of mortality and heart failure hospitalization in heart failure with preserved ejection fraction. Int J Obes (Lond). 2020;44(7):1561\u20137.","journal-title":"Int J Obes (Lond)"},{"issue":"22","key":"2626_CR25","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1016\/j.jacc.2017.09.1111","volume":"70","author":"T Tsujimoto","year":"2017","unstructured":"Tsujimoto T, Kajio H. Abdominal obesity is associated with an increased risk of all-cause mortality in patients with HFpEF. J Am Coll Cardiol. 2017;70(22):2739\u201349.","journal-title":"J Am Coll Cardiol."},{"issue":"18","key":"2626_CR26","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1177\/2047487318802695","volume":"25","author":"EH Van Iterson","year":"2018","unstructured":"Van Iterson EH, Kim CH, Uithoven K, Olson TP. Obesity and hemoglobin content impact peak oxygen uptake in human heart failure. Eur J Prev Cardiol. 2018;25(18):1937\u201346.","journal-title":"Eur J Prev Cardiol"},{"issue":"7","key":"2626_CR27","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1016\/j.amjcard.2013.12.031","volume":"113","author":"MJ Haykowsky","year":"2014","unstructured":"Haykowsky MJ, Kouba EJ, Brubaker PH, Nicklas BJ, Eggebeen J, Kitzman DW. Skeletal muscle composition and its relation to exercise intolerance in older patients with heart failure and preserved ejection fraction. Am J Cardiol. 2014;113(7):1211\u20136.","journal-title":"Am J Cardiol"},{"issue":"8","key":"2626_CR28","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.jchf.2018.06.002","volume":"6","author":"MJ Haykowsky","year":"2018","unstructured":"Haykowsky MJ, Nicklas BJ, Brubaker PH, et al. Regional adipose distribution and its relationship to exercise intolerance in older obese patients who have heart failre with preserved ejection fraction. JACC Heart Fail. 2018;6(8):640\u20139.","journal-title":"JACC Heart Fail"},{"issue":"11","key":"2626_CR29","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/ejhf.2337","volume":"23","author":"NR Pugliese","year":"2021","unstructured":"Pugliese NR, Paneni F, Mazzola M, et al. Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure. Eur J Heart Fail. 2021;23(11):1858\u201371.","journal-title":"Eur J Heart Fail"},{"issue":"6","key":"2626_CR30","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","volume":"27","author":"WJ Evans","year":"2008","unstructured":"Evans WJ, Morley JE, Argiles J, et al. Cachexia: a new definition. Clin Nutr. 2008;27(6):793\u20139.","journal-title":"Clin Nutr"},{"issue":"4","key":"2626_CR31","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","volume":"62","author":"WJ Paulus","year":"2013","unstructured":"Paulus WJ, Tschope C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. 2013;62(4):263\u201371.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2626_CR32","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.jacc.2019.05.052","volume":"74","author":"J Tromp","year":"2019","unstructured":"Tromp J, Shen L, Jhund PS, et al. Age-related characteristics and outcomes of patients with heart failure with preserved ejection fraction. J Am Coll Cardiol. 2019;74(5):601\u201312.","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2626_CR33","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.cardfail.2004.01.009","volume":"10","author":"FA Masoudi","year":"2004","unstructured":"Masoudi FA, Rumsfeld JS, Havranek EP, et al. Age, functional capacity, and health-related quality of life in patients with heart failure. J Card Fail. 2004;10(5):368\u201373.","journal-title":"J Card Fail"},{"issue":"6","key":"2626_CR34","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/j.hrtlng.2021.07.001","volume":"50","author":"KA Sethares","year":"2021","unstructured":"Sethares KA, Chin E. Age and gender differences in physical heart failure symptom clusters. Heart Lung. 2021;50(6):832\u20137.","journal-title":"Heart Lung"},{"issue":"5","key":"2626_CR35","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.hrtlng.2020.03.026","volume":"49","author":"KM Faulkner","year":"2020","unstructured":"Faulkner KM, Jurgens CY, Denfeld QE, Lyons KS, Harman TJ, Lee CS. Identifying unique profiles of perceived dyspnea burden in heart failure. Heart Lung. 2020;49(5):488\u201394.","journal-title":"Heart Lung"},{"issue":"1","key":"2626_CR36","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1161\/CIRCRESAHA.115.302929","volume":"115","author":"FS Loffredo","year":"2014","unstructured":"Loffredo FS, Nikolova AP, Pancoast JR, Lee RT. Heart failure with preserved ejection fraction: molecular pathways of the aging myocardium. Circ Res. 2014;115(1):97\u2013107.","journal-title":"Circ Res"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02626-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-022-02626-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02626-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T19:06:30Z","timestamp":1667415990000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-022-02626-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2626"],"URL":"https:\/\/doi.org\/10.1186\/s12916-022-02626-4","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,2]]},"assertion":[{"value":"6 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The TOPCAT trial was approved by the ethics committee and an informed consent form was signed by each participant. The present study was approved by the Medical Ethics Commission of the First Affiliated Hospital of Sun Yat-sen University, China ([2018]127).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"423"}}